Cochrane Abstracts
Eslicarbazepine acetate monotherapy for epilepsy
Abstract
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the efficacy and tolerability of eslicarbazepine acetate (ESL) monotherapy for focal onset seizures or generalised tonic‐clonic epilepsy in children and adults.
Author(s)
Xian‐Chao Chang, Hu Yu, Xiao‐Dan Zhang, Yi Wang, Wen‐Ke Hong, Dong‐Xing Wang
Reviewer's Conclusions
Citation
"Eslicarbazepine Acetate Monotherapy for Epilepsy." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy.
Eslicarbazepine acetate monotherapy for epilepsy. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy. Accessed December 11, 2024.
Eslicarbazepine acetate monotherapy for epilepsy. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy
Eslicarbazepine Acetate Monotherapy for Epilepsy [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 11]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Eslicarbazepine acetate monotherapy for epilepsy
ID - 437871
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437871/all/Eslicarbazepine_acetate_monotherapy_for_epilepsy
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
